Verismo Therapeutics Completes Merger to Accelerate Clinical Development
The merger will accelerate the clinical development of SynKIR™-110 and SynKIR™-310 for solid tumor and blood cancer patients, respectively, solidifying Verismo's and HLB Group's collective mission to advance its innovative KIR-CAR platform for patients worldwide.
HLB Innovation | 21/12/2024 | By Aishwarya | 158
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy